The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.60
Bid: 3.20
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.80 (25.00%)
Open: 3.60
High: 0.00
Low: 0.00
Prev. Close: 3.60
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

14 Dec 2015 16:02

RNS Number : 0056J
Proteome Sciences PLC
14 December 2015
 

 

 

PRESS RELEASE

 

14 December 2015

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Director Dealing

 

Further to the announcement made earlier today regarding the purchase of Ordinary Shares in the Company by Vulpes Life Sciences Fund ("Vulpes"), the Company would like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 36,548,125 Ordinary Shares of the Company representing 16.03% of the issued share capital of the Company.

 

 

For further information please contact:

 

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Ian Pike, Chief Operating Officer

Tel: +44 (0)1932 865065

Geoff Ellis, Finance Director

finnCap Limited (Nominated adviser & broker)

Geoff Nash/James Thompson

Tel: +44 (0)20 7220 0500

 

Public Relations

IKON Associates

Adrian Shaw

Email: Adrian@ikonassociates.com

Tel: +44 (0)1483 271291

Mob: +44 (0)797 9900733

Tel: +44 (0)1483 271291

Mob: +44 (0)7979 900733

 

 

 

Notes to Editors:

 

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

 

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

 

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFFAFILFISEIE
Date   Source Headline
10th Nov 201710:11 amRNSHolding(s) in Company
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
27th Oct 201711:30 amRNSHolding(s) in Company
27th Oct 201711:30 amRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSDirector/PDMR Shareholding
23rd Oct 201712:00 pmRNSHolding(s) in Company
20th Oct 201712:58 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSGCLP Accreditation and Trading Update
3rd Oct 20172:25 pmRNSBlock Admission Return
1st Sep 201712:08 pmRNSIssue of Equity
1st Aug 20177:00 amRNSDirectorate Changes
25th Jul 20177:00 amRNSInterim results for the 6 months to 30 June 2017
11th Jul 201712:00 pmRNSNotice of Results
30th Jun 201710:31 amRNSHolding(s) in Company
30th Jun 20177:00 amRNSStroke Diagnostic- Research Milestone Achieved
12th Jun 20177:00 amRNSNew Registered Address
8th Jun 20174:40 pmRNSSecond Price Monitoring Extn
8th Jun 20174:35 pmRNSPrice Monitoring Extension
15th May 20177:00 amRNSDirector/PDMR Shareholding
10th May 201710:09 amRNSDirector/PDMR Shareholding
5th May 201712:30 pmRNSDirector/PDMR Shareholding
4th May 20172:23 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20174:58 pmRNSDirector/PDMR Shareholding
28th Apr 20174:54 pmRNSHolding(s) in Company
25th Apr 20171:34 pmRNSAGM Statement and Result of AGM
11th Apr 20177:00 amRNSDirector Dealing and Total Voting Rights
4th Apr 20175:00 pmRNSHolding(s) in Company
4th Apr 20174:40 pmRNSSecond Price Monitoring Extn
4th Apr 20174:35 pmRNSPrice Monitoring Extension
4th Apr 20177:00 amRNSOption Awards
3rd Apr 20177:00 amRNSAppointment of Richard Dennis as CCO
31st Mar 20174:45 pmRNSBlock Admission Return
28th Mar 20177:00 amRNSPreliminary Results
9th Feb 20177:00 amRNSTrading Update & Notice of Results
4th Jan 20174:36 pmRNSHoldings in Company / PDMR Shareholding
3rd Jan 20171:34 pmRNSHoldings in Company / PDMR Shareholding
30th Dec 201611:42 amRNSHolding(s) in Company
19th Dec 20167:00 amRNSLaunch of new website
16th Dec 20169:28 amRNSHolding(s) in Company
29th Nov 201610:43 amRNSResult of GM and Completion of Placing
18th Nov 20169:46 amRNSHolding(s) in Company
8th Nov 201610:12 amRNSHolding(s) in Company
4th Nov 20163:52 pmRNSDirector/PDMR Shareholding & Total Voting Rights
2nd Nov 20164:35 pmRNSPrice Monitoring Extension
31st Oct 20167:00 amRNSPlacing and Subscription to raise £3.3 million
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
4th Oct 20164:35 pmRNSPrice Monitoring Extension
3rd Oct 20167:00 amRNSBlock Admission return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.